Investing in Corcept Therapeutics carries distinct risks typical of the commercial-stage biotechnology and pharmaceutical sectors, most notably regulatory approval uncertainties, clinical trial execution timelines, and potential legal challenges concerning intellectual property and patent protections. Additionally, the company faces commercial execution risks regarding physician adoption rates for its cortisol-modulating treatments, potential competitive market entries from rival pharmaceutical developers, and overall market volatility affecting high-growth healthcare equities.